Most of the patients with stage I adenocarcinoma were grouped into the low-MAFB+ (stage I: stage III, 24:6), while a significant number of patients with stage III adenocarcinoma were grouped into the high-MAFB+ group (stage I:stage III, 3:28, p < 0.01). Here, MAFB is linked to adenocarcinoma.